Inlyta

(axitinib)

Inlyta 1 MG Oral TabletInlyta 5 MG Oral Tablet

NO BLACK BOX WARNING

Dosage & administration

* INLYTA 5 mg orally twice daily with avelumab 800 mg every 2 weeks.
* INLYTA 5 mg orally twice daily with pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks.
* INLYTA as a single agent the starting dose is 5 mg orally twice daily.
* Dose adjustments can be made based on individual safety and tolerability.
* Administer INLYTA dose approximately 12 hours apart with or without food.
* INLYTA should be swallowed whole with a glass of water.
* See Full Prescribing Information for dosage modifications for adverse reactions.
* If a strong CYP3A4/5 inhibitor is required, decrease the INLYTA dose by approximately half.
* For patients with moderate hepatic impairment, decrease the starting dose by approximately half.

Most viewed Inlyta resources

Enroll in Patient Savings Program

biomarker testing

Inlyta clinical details

Genetic testing requirements were obtained from the NCCN guidelines for each cancer type.

drug label

Inlyta prescribing information

Contact Medical Science Liaison Report Adverse Event

samples

Request Inlyta samples

OTHEROnline Sample Form

Learn More

prior authorization

Inlyta prior authorization resources

PDFComplete Letter of Medical Necessity

PDFCoverage Authorization Appeals

PDFFormulary Exception Letter

Learn More

Benefits investigation

PDFPfizer Oncology Together Form

PDFPfizer Oncology Together Form - Spanish

Learn More

Reimbursement help (FRM)

OTHERReceive Assistance from an FRM Regarding Reimbursement Information

Learn More

pharmacy

Inlyta preferred pharmacy

PDFPharmacy List

financial assistance

Inlyta financial assistance options

Co-pay savings program

commercial only

Enroll in Patient Savings Program

OTHERHCP Office: Attest & Print Co-Pay Card

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

under insured

no insurance

goverment insurance

65+

PDFPfizer Oncology Together Form

PDFPfizer Oncology Together Form - Spanish

OTHERPfizer Patient Assistance Program

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.